

ELMUMY



BRIEFING NOTE

The research proposal ELMUMY (Elucidation of risk factors and health determinants associated with progression of Monoclonal Gammopathies to Multiple Myeloma), submitted under the Horizon Europe HORIZON-MISS-2021-CANCER-02 call, has been selected for funding by the European Commission, having achieved the highest score of all proposals that were submitted (14.5/15). For the implementation of the ELMUMY project a multinational consortium of 13 participating organizations (research institutes, academic institutions, and innovative biotechnology companies) has been created. **The aim of the project is to investigate the molecular mechanisms involved in the pathogenesis and progression of the disease and to find innovative treatment regimens tailored to the specific characteristics of each patient.** This European consortium promotes the interdisciplinary communication by bringing together clinicians and researchers with expertise in Multiple Myeloma (MM), epidemiology, mouse models, omics, bioinformatics, and artificial intelligence (AI) methods. This consortium with a budget of 10 million euros is coordinated by Professor Meletios-Athanasios Dimopoulos, Rector of the National and Kapodistrian University of Athens (NKUA). The institute of Chemical biology at the National Hellenic Research Foundation (Dr. Vassilis Souliotis and Dr. Dimitris Stellas) has undertaken the subsequent coordination of the studies regarding the molecular biology and the humanized patient derived in vivo models. It is

noteworthy that the ELMUMY Consortium, despite NKUA and NHRF also includes several European reference centers for multiple myeloma and academic institutions from different European countries, such as, UNIVERSITA DEGLI STUDI DI TORINO (Italy), UNIVERSIDAD DE NAVARRA (Spain), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (France), UNIVERSITAETS KLINIKUM WUERZBURG – KLINIKUM DER BAYERISCHE JULIUS-MAXIMILIANS-UNIVERSITAT, GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER (Germany), and THE CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS (Cyprus). Exelixis Research Management & Communication (Greece), MOSAIQUES DIAGNOSTICS GMBH (Germany), ATOS IT SOLUTIONS AND SERVICES IBERIA SL (Spain).